Jounce Therapeutics Inc logo

Jounce Therapeutics Inc Share Price (NASDAQ: JNCE)

▲

-1.88

(-100%)

Last updated on

Bell Icon

The stock has been delisted from the stock exchange on 3 May 2023

Check the interactive Jounce Therapeutics Inc Stock chart to analyse performance

Jounce Therapeutics Inc Key Stats

Check Jounce Therapeutics Inc key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close
$1.88
Open
$1.92
Market Capitalization
$100.5M
Today's Volume
$11.6M
Revenue TTM
$82.0M
EBITDA
$-50.2M
Earnings Per Share (EPS)
$-0.98
Dividend Yield
0.0%
Profit Margin
-62.1%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-25.03%

Global Institutional Holdings in Jounce Therapeutics Inc

  • Name

    Holdings %

  • RTW INVESTMENTS, LLC

    9.75%

  • Deep Track Capital, LP

    8.14%

  • COWEN AND COMPANY, LLC

    6.97%

  • Bank of America Corp

    6.26%

  • BlackRock Inc

    4.91%

  • Millennium Management LLC

    3.49%

Analyst Recommendation on Jounce Therapeutics Inc Stock

Rating
Trend

Buy

    76%Buy

    23%Hold

    0%Sell

Based on 13 Wall street analysts offering stock ratings for Jounce Therapeutics Inc(by analysts ranked 0 to 5 stars)

About Jounce Therapeutics Inc

Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. It develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors. The company is also developing JTX-8064, a monoclonal antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages; and Pimivalimab, an anti-PD-1 antibody for combination therapy. In addition, its preclinical products are JTX-1484, a monoclonal antibody designed to reduce myeloid-mediated immune suppression; and JTX-2134, a monoclonal antibody designed to reduce myeloid-mediated immune suppression and activate T and NK cells. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.
Organization
Jounce Therapeutics Inc
Employees
141
CEO
Dr. Richard Murray Ph.D.
Industry
Health Technology

Important FAQs about investing in JNCE Stock from India :

What is Jounce Therapeutics Inc share price today?

Jounce Therapeutics Inc share price today is as on at the close of the market. Jounce Therapeutics Inc share today touched a day high of {{1_rba_end}} and a low of {{1_rba_st}}.

What is the 52 week high and 52 week low for Jounce Therapeutics Inc share?

Jounce Therapeutics Inc share touched a 52 week high of {{rba_end}} and a 52 week low of {{rba_st}}. Jounce Therapeutics Inc stock price today i.e. is closed at , lower by 100% versus the 52 week high.

How to invest in Jounce Therapeutics Inc Stock (JNCE) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Jounce Therapeutics Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Jounce Therapeutics Inc Shares .

What is the minimum amount required to buy Jounce Therapeutics Inc Stock (JNCE) from India?

Indian investors can start investing in Jounce Therapeutics Inc (JNCE) shares with as little as ₹88.097 or $1 (as of September 18, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹880.97 in Jounce Therapeutics Inc stock (as per the Rupee-Dollar exchange rate as on September 18, 2025). Learn more about fractional shares .

What are the returns that Jounce Therapeutics Inc has given to Indian investors in the last 5 years?

Jounce Therapeutics Inc stock has given 0.0% share price returns and 19.79% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?